Molecular Diagnostic Tools for Patient Oriented Field Studies in Infectious Diseases

我是弗吉尼亚大学传染病科的临床研究员， 这一次K24更新申请，以进一步扩大我的分子诊断研究，以病人为导向， 研究（POR），并提供受保护的时间来指导我的直接和机构学员。在15 自从完成ID奖学金以来，我已经在热带的几个领域制定了一个研究计划。 传染病，现在主要集中在分子诊断工具的研究开发。目标1： 在第一个任期内，我设立了弗吉尼亚大学医学院K奖指导 计划，这需要一系列的研讨会和会议，面向双方申请和那些 已经获得NIH K或类似奖项的人。这K24赠款将允许我继续和扩展这一点， 更重要的计划。这笔赠款还将允许受保护的时间直接指导我的学员在POR， 目前由3名K23接受者和1名传染病研究员组成，在MDR领域工作 结核病、儿童结核病、儿童腹泻和抗菌素耐药性，每一个都有诊断重点。目标2： 我也将把我的个人研究项目扩展到POR。目前资助的工作包括使用分子 腹泻的病例和人群水平病原学诊断和MDR的分子诊断 结核最成熟的工作涉及到牙周炎的病因学，我们的最新数据有力地支持进入 肠杆菌的临床试验大肠杆菌疫苗和新的隐孢子虫疗法。K24将 给我一些时间把这些分子诊断作为主要或次要的试验 获得临床试验设计和数据分析所需的技能。最后，与K24一致 机制，我将扩大我的研究新领域，如耐药性的分子诊断。

I am a Clinician Investigator in the Division of Infectious Diseases at University of Virginia and am submitting this one-time K24 renewal application to further extend my molecular diagnostics research into patient oriented research (POR) and to provide protected time to mentor both my direct and institutional trainees. In the 15 years since completion of ID fellowship I have developed a research program in several domains of tropical infectious diseases, now largely focused on the development of molecular diagnostic tools for research. Aim 1: In the first term of this grant I established the University of Virginia School of Medicine K-award mentoring program, which entails a series of Symposia and meetings geared towards both those applying for and those who have already received NIH K or similar awards. This K24 grant will allow me to continue and extend this important program further. This grant will also allow protected time to directly mentor my trainees in POR, which currently consists of 3 K23 recipients and 1 Infectious Disease fellow, working in areas spanning MDR TB, pediatric TB, childhood diarrhea, and antimicrobial resistance, each with a diagnostic emphasis. Aim 2: I will also extend my personal research program into POR. Currently funded work includes the use of molecular diagnostics for both case- and population-level etiologic diagnosis of diarrhea and molecular diagnosis of MDR Tuberculosis. The most mature work involves diarrheal etiology, and our latest data strongly supports entering into clinical trials for Enterotoxigenic E. coli vaccines and new Cryptosporidium therapeutics. This K24 will allow me protected time to insert these molecular diagnostics into these trials as primary or secondary outcomes and gain needed skills in clinical trial design and data analysis. Finally, consonant with the K24 mechanism, I will expand my research new areas such as molecular diagnostics for antimicrobial resistance.